{
    "clinical_study": {
        "@rank": "16483", 
        "acronym": "HBP-Neupogen", 
        "arm_group": [
            {
                "arm_group_label": "Filgrastim", 
                "arm_group_type": "Active Comparator", 
                "description": "Filgrastim 300 microgr/day subcutaneously for 7 days"
            }, 
            {
                "arm_group_label": "NaCl 0.9%", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Corresponding placebo once daily, subcutaneously for 7 days"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study of plasma HBP -levels of a previously published trial of G-CSF in critically\n      ill patients (Pettila et al. Critical Care Medicine 2000). The original study was a\n      prospective, randomised, double-blind, placebo-controlled trial of filgrastim in patients\n      with acute respiratory failure requiring intubation. In this substudy, the investigators\n      evaluated the effect of filgrastim on HBP -concentrations in critically ill patients."
        }, 
        "brief_title": "Heparin Binding Protein in Patients With Acute Respiratory Failure Treated With GCSF (Filgrastim)", 
        "completion_date": {
            "#text": "September 1998", 
            "@type": "Actual"
        }, 
        "condition": [
            "Acute Respiratory Failure", 
            "Critically Ill"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Critical Illness", 
                "Respiratory Distress Syndrome, Adult", 
                "Respiratory Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Criteria for original study. For the substudy, all these patients were included.\n\n        Inclusion Criteria:\n\n          -  Age > 18 years\n\n          -  Admitted to the ICU no longer than 12 hrs before study entry\n\n          -  Intubated because of ventilation insufficiency no longer than 48 hrs before study\n             entry\n\n          -  Clinically expected stay in the ICU > 48 hrs\n\n          -  Informed consent\n\n        Exclusion Criteria:\n\n          -  Pregnant or nursing\n\n          -  Total leukocyte count of > 50,000/mm3\n\n          -  Administration of filgrastim, sargramostim, or other biological response modifiers\n             within 7 days before study entry\n\n          -  Known hypersensitivity or allergic reaction to Escherichia coli-derived products\n\n          -  Participation in another drug study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "59", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01713309", 
            "org_study_id": "HBP01"
        }, 
        "intervention": {
            "arm_group_label": "Filgrastim", 
            "description": "Filgrastim 300 ug daily for 7 days, subcutaneously.", 
            "intervention_name": "Filgrastim", 
            "intervention_type": "Drug", 
            "other_name": "Neupogen"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Heparin", 
                "Lenograstim"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Filgrastim", 
            "G-CSF", 
            "Heparin-binding protein", 
            "critically ill", 
            "acute respiratory failure"
        ], 
        "lastchanged_date": "October 25, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Helsinki", 
                    "country": "Finland", 
                    "zip": "00029"
                }, 
                "name": "Helsinki University Central Hospital"
            }
        }, 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Heparin Binding Protein in Patients With Acute Respiratory Failure Treated With Granulocyte Colony-stimulating Factor (Filgrastim)", 
        "other_outcome": {
            "description": "cytokines, IL-6, TNF, phospolipase A2 and BPIP (=bacterial permeability increasing protein)", 
            "measure": "inflammatory mediators", 
            "safety_issue": "No", 
            "time_frame": "up to day 7"
        }, 
        "overall_official": [
            {
                "affiliation": "Helsinki University Central Hospital", 
                "last_name": "Ville Pettila, MD, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Helsinki University Central Hospital", 
                "last_name": "Kirsi-Maija Kaukonen, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Finland: Ethics Committee", 
                "Finland: National Agency of Medicines 17 Dec 1996/ Dno: 287/853/96 (the name on your listing is the name the agency has today. In 1996 it was National Agency of Medicines)", 
                "Finland: Finnish Medicines Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "June 1998", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "the number of patients developing ARDS, disseminated intravascular coagulation or acute renal failure during days 1-28, and changes in MOD score during days 1-7.", 
            "measure": "Number of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "up to 28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01713309"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Helsinki University Central Hospital", 
            "investigator_full_name": "Kirsi-Maija Kaukonen", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": [
            {
                "PMID": "11098963", 
                "citation": "Pettil\u00e4 V, Takkunen O, Varpula T, Markkola A, Porkka K, Valtonen V. Safety of granulocyte colony-stimulating factor (filgrastim) in intubated patients in the intensive care unit: interim analysis of a prospective, placebo-controlled, double-blind study. Crit Care Med. 2000 Nov;28(11):3620-5."
            }, 
            {
                "PMID": "15883741", 
                "citation": "Takala A, Pettil\u00e4 V, Takkunen O, Rintala E, Kautiainen H, Repo H. Granulocyte colony-stimulating factor therapy and systemic inflammation in critically ill patients. Inflamm Res. 2005 Apr;54(4):180-5."
            }
        ], 
        "secondary_outcome": {
            "description": "frequency of nosocomial infections, length of mechanical ventilatory support, length of stay in the ICU, 28-day mortality rate, 90-day mortality rate, and laboratory values for neutrophil count", 
            "measure": "follow up measures", 
            "safety_issue": "Yes", 
            "time_frame": "Up to day 90"
        }, 
        "source": "Helsinki University Central Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "The Swedish Research Council", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Helsinki University Central Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 1996", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}